Answers are grounded in this paper and cite their sources.
Background: Tumor hypoxia is a major metabolic barrier that limits CAR-T cell persistence and antitumor efficacy in solid tumors. Here, we identify arginase 2 (ARG2) as a critical cell-intrinsic mediator of hypoxia-induced CAR-T cell dysfunction. Methods: Using MSLN and CD70 specific CAR-T cells, we evaluated three complementary strategies to target ARG2: pharmacological inhibition with BEC, extracellular L-arginine supplementation, and CRISPR-Cas9-mediated ARG2 knockout. CAR-T cell function, exhaustion, and memory differentiation were assessed under hypoxic conditions (1% O₂) by serial killing assays, cytokine detection, and flow cytometry. In vivo efficacy was evaluated in a xenograft tumor model, and transcriptomic profiling was performed to delineate underlying molecular mechanisms. Results: Hypoxia markedly upregulated ARG2 expression in CAR-T cells independent of antigen specificity. Pharmacological ARG2 inhibition with BEC (10 μM) restored sustained cytotoxicity and pro-inflammatory cytokine secretion (IFN-γ and TNF-α), reduced exhaustion markers (PD-1 and LAG-3), and promoted a durable memory phenotype by enriching stem cell memory (TSCM) and central memory (TCM) subsets while decreasing terminal effector (TTE) cells. L-arginine supplementation (2 mM) similarly enhanced cytotoxic function and alleviated exhaustion but failed to remodel memory differentiation, indicating mechanistic distinctions between substrate replenishment and enzymatic blockade. Genetic ARG2 knockout recapitulated these protective effects, preserving cytolytic activity and increasing CD62L⁺ memory-like populations under hypoxia. In vivo, both BEC- and L-Arg-pretreated CAR-T cells improved tumor control, enhanced circulating persistence, reduced exhausted T cell frequencies, and increased intratumoral CD45⁺ infiltration without overt toxicity, with BEC specifically elevating TCM proportions. Transcriptomic analysis revealed that ARG2 ablation triggered broad transcriptional reprogramming, with enrichment of PI3K-AKT signaling, stem cell pluripotency pathways, and glycine/serine/threonine metabolism. IGF2, a well-documented upstream activator of the PI3K-AKT axis, was significantly upregulated in ARG2-deficient cells at both the transcriptomic and qPCR validation levels, suggesting it may serve as a downstream mediator of ARG2 deficiency that drives PI3K-AKT pathway activation. Conclusions: These findings establish ARG2 as a pivotal regulator of hypoxia-driven CAR-T cell dysfunction and support ARG2-targeted interventions—particularly pharmacological inhibition—as a promising strategy to enhance metabolic fitness, memory phenotype, and therapeutic durability against solid tumors.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: